Laboratory Performance of the DopaFuse® Delivery System
Objective: SynAgile has developed the DopaFuse Delivery System to noninvasively and continuously administer levodopa/carbidopa (LD/CD) into the mouths of patients with Parkinson’s Disease (PD). The…STAT-ON: a Wearable Inertial System to Objectively Evaluate Motor Symptoms in Parkinson’s Disease
Objective: We present a wearable inertial system for the evaluation of motor symptoms in Parkinson's Disease. Background: PD is the second neurodegenerative disease affecting to around…A Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson’s Disease Complicated By “OFF” Episodes
Objective: To assess the effect of apomorphine sublingual film (APL130277; APL) on the QT interval in patients with Parkinson’s disease (PD) and “OFF” episodes participating…Effect of an Increase in Dose of Istradefylline, an A2A Receptor Antagonist, in Levodopa (LD)-Treated Patients with Parkinson’s Disease (PD)
Objective: To observe whether increasing the istradefylline dose from 20 to 40mg/day provides more patients with meaningful clinical responses. Background: Istradefylline, a well-tolerated selective adenosine…Does information from the Personal KinetiGraph™ (PKG) influence neurologists´ treatment decisions?
Objective: To evaluate if PKG data influences neurologists´ treatment decisions in routine clinical care of patients with Parkinson´s disease. Background: The PKG movement recording system is…A characterization of the ADL-level in daily life with Parkinson`s Disease based on objective measurements and subjective experiences.
Objective: 1. Test whether slow response to the medication and EMO-periods (Early Morning Off), affects the patient`s experience of being able to perform ADL-functions. 2.…Efficacy of Istradefylline, an A2A Receptor Antagonist, When Added to Levodopa (LD) and Other Medications for Parkinson’s Disease (PD)
Objective: To evaluate the clinical effect of istradefylline as adjunctive treatment to LD in PD patients with or without additional PD medications (meds). Background: Istradefylline,…Population Exposure-Response Models of Apomorphine Sublingual Film in Healthy Subjects and Patients With Parkinson’s Disease and “OFF” Episodes
Objective: Exposure-response models were developed to characterize the relationship between apomorphine exposure and (1) efficacy using Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease…NS-PARK cohort: a nationwide real life longitudinal cohort of PD patients
Objective: To describe the Parkinson disease (PD) population followed by the 25 expert centers for PD in France. Background: NS-PARK is the clinical research network…Assessing the validity and reliability of MANAGE-PD tool to identify patients with Parkinson’s disease inadequately controlled on oral medications – Results from an international survey of general neurologists and movement disorder specialists
Objective: To evaluate the validity and reliability of MANAGE-PD tool. Background: Timely identification of advancing symptoms in patients with Parkinson’s Disease (PD), thereby improving opportunities…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 26
- Next Page »